Andrew Doig

Andrew Doig is a Professor of Biochemistry at The University of Manchester, affiliated with the Division of Molecular & Cellular Function. His research focuses on Alzheimer’s Disease, proteomics, and drug discovery, particularly targeting amyloid-beta aggregation and toxicity. He also explores protein vibrational spectroscopy for structural analysis, and engineering GFP to reduce immunogenicity.

Doig holds a PhD in Biochemistry from the University of Cambridge (1991). His teaching includes courses on protein processing, Alzheimer’s, and prion diseases. He collaborates with Senexis, a spin-out company, to develop Alzheimer’s treatments. His work integrates computational methods with experimental techniques, such as machine learning for gene prioritization and proteomics/metabolomics to study cellular responses to amyloid peptides.

Research interests span drug target identification, using graph theory to analyze protein datasets, and understanding amyloid’s role in neurodegenerative and metabolic disorders like type 2 diabetes. His contributions include novel inhibitors of amyloid aggregation and insights into viral involvement in Alzheimer’s pathogenesis.